Pfizer Confirms NYSE Listing for Common Stock, 1.000% Notes Due 2027

TL;DR

**Pfizer's common stock and 2027 notes are officially listed on the NYSE, confirming their public trading status.**

AI Summary

Pfizer Inc. filed an 8-K on January 10, 2024, to update its registered securities. The filing confirms that both its Common Stock, with a $.05 par value, and its 1.000% Notes due 2027 are registered on the New York Stock Exchange under the trading symbols PFE and PFE27, respectively. This matters to investors as it reaffirms the liquidity and public trading status of these key securities, providing transparency on where they can be bought and sold.

Why It Matters

This filing provides clarity on Pfizer's publicly traded securities, ensuring investors know where to find and trade its common stock and specific debt instruments.

Risk Assessment

Risk Level: low — This filing is purely administrative, confirming existing security registrations, and introduces no new financial or operational risks.

Analyst Insight

Investors should note this filing as a routine administrative update, confirming the public trading status of Pfizer's common stock and specific debt. It doesn't suggest any immediate action but reinforces the transparency of their listed securities.

Key Numbers

• $0.05 — par value per share (for Pfizer's Common Stock)
• 1.000% — interest rate (for Pfizer's Notes due 2027)
• 2027 — maturity year (for Pfizer's Notes)

Key Players & Entities

• PFIZER INC (company) — the registrant filing the 8-K
• New York Stock Exchange (company) — the exchange where Pfizer's securities are registered
• $0.05 (dollar_amount) — par value of Pfizer's Common Stock
• PFE (company) — trading symbol for Pfizer's Common Stock
• PFE27 (company) — trading symbol for Pfizer's 1.000% Notes due 2027

FAQ

From the Filing

0000078003-24-000006.txt : 20240110 0000078003-24-000006.hdr.sgml : 20240110 20240110163830 ACCESSION NUMBER: 0000078003-24-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240110 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 24527021 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20240110.htm PFIZER 8-K JANUARY 10 2024 pfe-20240110 0000078003 false 0000078003 2024-01-10 2024-01-10 0000078003 us-gaap:CommonStockMember 2024-01-10 2024-01-10 0000078003 pfe:NotesDue20271.000Member 2024-01-10 2024-01-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 8.01.   Other Events. Pfizer Inc. (the “Company”) has received notice of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (“TRC Capital”) to purchase up to 4,000,000 shares of the Company's common stock at a cash offer price of $27.35 per share, which is approximately 4.4 percent lower than the $28.61 per share closing price for a share of the Company's common stock on December 27, 2023, the business day prior to the date of the offer. The shares subject to TRC Capital's offer represent appr